Skip to main content

Month: August 2024

The Public Cloud Market: A $987.7 billion Industry Dominated by | AWS, Microsoft, Google, Salesforce, Alibaba Cloud MarketsandMarkets™

Chicago, Aug. 07, 2024 (GLOBE NEWSWIRE) — The Public Cloud Market size is expected to grow from USD 444.7 billion in 2022 to USD 987.7 billion by 2027 at a Compound Annual Growth Rate (CAGR) of 17.3% during the forecast period according to report by MarketsandMarkets. The term “public cloud” refers to offering numerous cloud services to various enterprises at the same time (as well as the general public) on-demand access to storage, computing, and networking services over the Internet. The public cloud providers offer free or fee-based usage-based pricing models for public cloud services. AWS, Microsoft, and Google are one of the major cloud service providers that run and administer public clouds. Browse in-depth TOC on “Public Cloud Market” 213 – Tables 50 – Figures 288 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=75044022 Public...

Continue reading

Team, Inc. Announces Timing of Second Quarter Earnings Release and Conference Call

SUGAR LAND, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) — Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global, leading provider of specialty industrial services offering clients access to a full suite of conventional, specialized, and proprietary mechanical, heat-treating, and inspection services, today announced that it will issue its second quarter 2024 earnings release on Thursday, August 8, 2024 after the close of trading on the New York Stock Exchange. TEAM will host a conference call to discuss its financial and operational results on Friday morning, August 9, 2024 at 10:00 a.m. Central Time (11:00 a.m. Eastern Time). Interested parties in the United States may participate toll-free by dialing (877) 270-2148. Interested parties internationally may dial (412) 902-6510. Participants should ask to join “TEAM, Inc. Second Quarter...

Continue reading

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2024 financial results on Wednesday, August 14, 2024. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: Call: (800) 225-9448 / international call: (203) 518-9708 Archive: (800) 934-7884 / international archive: (402) 220-6987  Code for live and archived conference call is CYCCQ224. Webcast link For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for 90 days...

Continue reading

Mullen Announces Promotion of John Taylor to President of Commercial EV Division

Taylor also retains role as SVP of Global Manufacturing for Mullen Automotive In 2010, John joined Tesla and was one of the first 50 employees, leading the advanced manufacturing engineering group. Taylor played a critical role in opening Tesla’s Fremont facility and manufacturing operations for the Tesla Model S and architecture for future EV projects BREA, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) — via IBN — Mullen Automotive Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an electric vehicle (“EV”) manufacturer, today announces John Taylor as president of Mullen’s commercial EV division. Taylor also retains position of senior vice president of global manufacturing for Mullen Automotive.  Since joining Mullen in 2021, Taylor has played a pivotal role in the development and successful launch of the Mullen ONE Class 1 EV cargo...

Continue reading

SEALSQ Receives Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Geneva, Switzerland, Aug. 07, 2024 (GLOBE NEWSWIRE) — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI and Post-Quantum technology hardware and software products, today announced that on August 1, 2024, it received a notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”), stating that the Company’s ordinary shares, par value US$0.01 per ordinary share (the “Ordinary Shares”), fail to comply with the $1.00 minimum bid price requirement for continued listing on Nasdaq in accordance with Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the Company’s Ordinary Shares for the last 30 consecutive business days prior to the date of the Notice. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided...

Continue reading

ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference

SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the 2024 Wedbush PacGrow Healthcare Conference being held August 13-14, 2024 in New York City. Company management will participate in one-on-one meetings with investors on Wednesday, August 14, 2024. About ARS Pharmaceuticals, Inc.ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The Company is developing neffy (also referred to as ARS-1), an intranasal epinephrine product in clinical development...

Continue reading

Alpha Pro Tech, Ltd. Announces Second Quarter 2024 Financial Results

Net income for the quarter ended June 30, 2024 was $1.6 million or $0.15 per diluted share, compared to net income of $1.1 million, or $0.10 per diluted share, for the same period of 2023, representing an increase of $498,000, or 43.5%Net sales for the second quarter of 2024 were $16.3 million, up 1.1%, compared to $16.1 million for the second quarter of 2023Building Supply segment sales decreased by $596,000 or 5.7%, to $9.9 million, compared to $10.5 million for the three months ended June 30, 2023 Disposable Protective Apparel segment sales increased by 13.8%, to $6.3 million, compared to $5.6 million for the same period of 2023Net income for the second quarter of 2024 was $1.6 million, or $0.15 per diluted share, compared to $1.1 million, or $0.10 per diluted share, for the second quarter of 2023 Cash and cash equivalents of...

Continue reading

REMINDER: Rogers Sugar Inc.: Conference Call – 3rd Quarter 2024 Results

VANCOUVER, British Columbia, Aug. 07, 2024 (GLOBE NEWSWIRE) — Rogers Sugar Inc. (RSI) will be holding a conference call to discuss their 2024 third quarter results on Thursday, August 8, 2024, at 17h30 (Eastern Time). The conference call will be chaired by Mr. Michael Walton, Chief Executive Officer and Mr. Jean-Sébastien Couillard, Chief Financial Officer. If you wish to participate, please dial 1-800-717-1738. A recording of the conference call will be accessible shortly after the conference, by dialing 1-877-674-7070, access code 30571#. This recording will be available until August 8, 2025. The discussion along with a presentation will be accessible through a webcast at the following address: https://onlinexperiences.com/Launch/QReg/ShowUUID=2F8B1C1C-121F-4AEA-858F-53569C0604ED&LangLocaleID=1033 For further information: Jean-Sébastien...

Continue reading

Grayscale Investments® Launches Two New Product Offerings: Grayscale® Bittensor Trust and Grayscale® Sui Trust

Creation of new Trusts reflects Grayscale’s desire to meet growing investor demand for diversified crypto exposure STAMFORD, Conn., Aug. 07, 2024 (GLOBE NEWSWIRE) — Grayscale Investments®, the world’s largest crypto asset manager*, offering more than 20 crypto investment products, today announced the creation and public launch of two new crypto investment trusts: Grayscale® Bittensor Trust and Grayscale® Sui Trust (collectively “the Trusts”). Grayscale® Bittensor Trust is solely invested in TAO, the token underpinning the Bittensor protocol, which leverages tokens to incentivize the development of open-source AI. Grayscale® Sui Trust is focused solely on investing in SUI, the token underpinning the Sui protocol, a high-performance Layer 1 smart contract blockchain designed to enable globally scalable decentralized applications. “We...

Continue reading

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04 Topline results expected during the fourth quarter GLEN ALLEN, Va., Aug. 07, 2024 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced that the final patient has completed the last dose in the pharmacokinetics study of AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day). Topline results from both cohorts are expected to be announced during the fourth quarter of 2024. Cary...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.